Study guide

17.4 Complementary, Alternative & Integrative Therapies in Oncology

BCOP Board Certified Oncology Pharmacist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & BCOP Exam Foundations

1.1 BCOP Exam Specifications, Passing Standard & Eligibility 1.2 The Clinical Oncology Pharmacist Scope of Practice & Core Competencies 1.3 Study Guide Methodology & Active Learning Strategy

2 Chapter 2: Cancer Biology & Pathophysiology

2.1 Hallmarks of Cancer, Multi-Step Carcinogenesis & Tumor Microenvironment 2.2 Cell Cycle Checkpoints, Apoptotic Pathways & DNA Damage Repair Mechanics 2.3 Tumor Immunology, Antigen Presentation & Mechanisms of Immune Evasion

3 Chapter 3: Genomic Biomarkers & Molecular Targets

3.1 Somatic vs Germline Mutations, NGS Profiling & Variant Classification 3.2 Actionable Oncogenic Driver Mutations & Targeted Kinase Inhibitors 3.3 Pharmacogenomics in Oncology: DPYD, TPMT, NUDT15, UGT1A1 & CYP2D6

4 Chapter 4: Diagnostics, Staging & Clinical Assessment

4.1 Circulating Tumor Markers, Flow Cytometry & Diagnostic Modalities 4.2 TNM Staging Systems, Histopathologic Grading & Hematologic Prognostic Indices 4.3 Performance Status Scales & Organ Function Assessment 4.4 Cancer Screening, Early Detection & Prevention

5 Chapter 5: Cytotoxic Chemotherapy Pharmacology & Regimens

5.1 Alkylating Agents & Platinum Analogs 5.2 Antimetabolites & Folate Antagonists 5.3 Topoisomerase Inhibitors, Anthracyclines & Cardiotoxicity Mitigation 5.4 Antimicrotubule Agents: Taxanes, Vinca Alkaloids & Halichondrins

6 Chapter 6: Targeted Small-Molecule Therapies

6.1 Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumors 6.2 Hematologic Small-Molecule Kinase Inhibitors 6.3 Pathway-Specific Inhibitors: PARP, CDK4/6, BCL-2 & PI3K/AKT/mTOR Pathways

7 Chapter 7: Immunotherapy, Biologics & Cellular Therapy

7.1 Immune Checkpoint Inhibitors & irAE Management 7.2 Naked Monoclonal Antibodies, Antibody-Drug Conjugates & Bispecific T-Cell Engagers 7.3 Chimeric Antigen Receptor (CAR) T-Cell Therapies & Cellular Logistics

8 Chapter 8: Breast & Gynecologic Malignancies

8.1 Early-Stage & Locoregional Breast Cancer 8.2 Advanced & Metastatic Breast Cancer Targeted Strategies 8.3 Epithelial Ovarian, Endometrial & Cervical Malignancies

9 Chapter 9: Thoracic & Skin Malignancies

9.1 Early & Locally Advanced NSCLC & Small Cell Lung Cancer 9.2 Metastatic Non-Small Cell Lung Cancer (Driver-Positive and Driver-Negative) 9.3 Cutaneous Melanoma & Non-Melanoma Skin Cancers

10 Chapter 10: Gastrointestinal & Genitourinary Malignancies

10.1 Colorectal Cancer: Staging, Adjuvant Therapy, and Biomarker-Driven Metastatic Therapeutics 10.2 Esophagogastric, Pancreatic, and Hepatobiliary Malignancies 10.3 Genitourinary Malignancies: Prostate, Renal Cell, and Urothelial Carcinomas

11 Chapter 11: Hematologic Malignancies: Leukemias & Myeloma

11.1 Acute Myeloid & Acute Lymphoblastic Leukemias 11.2 Chronic Leukemias & Myeloproliferative Neoplasms 11.3 Multiple Myeloma & Plasma Cell Dyscrasias 11.4 Non-Malignant Hematologic Disorders: ITP, Aplastic Anemia, Sickle Cell Disease & TTP

12 Chapter 12: Lymphomas & Stem Cell Transplantation

12.1 Classical Hodgkin Lymphoma: Staging, Frontline Regimens & Relapsed/Refractory Strategies 12.2 Non-Hodgkin Lymphomas: Aggressive, Indolent, Mantle Cell & T-Cell Subtypes 12.3 Hematopoietic Stem Cell Transplantation, Complications & Graft-versus-Host Disease

13 Chapter 13: Supportive Care & Toxicity Management

13.1 Chemotherapy-Induced Nausea and Vomiting (CINV) Prophylaxis & Rescue 13.2 Myelosuppression, Febrile Neutropenia & Growth Factor Stewardship 13.3 Oncologic Emergencies: TLS, Hypercalcemia, Spinal Cord Compression & SVCS 13.4 Chemotherapy Extravasation, Organ Protectants & Antidotes

14 Chapter 14: Hazardous Drug Handling & Compounding Safety

14.1 USP <800> & NIOSH Hazardous Drug Standards 14.2 Engineering Controls, Personal Protective Equipment & Closed System Transfer Devices 14.3 Safe Handling, Surface Decontamination & Accidental Spill Response

15 Chapter 15: Chemotherapy Safety, Dosing & Order Verification

15.1 Regimen Standardization, Dose Calculation Formulas & Organ Adjustments 15.2 Independent Double-Check, Verification Checkpoints & Toxicity Gating 15.3 Oral Chemotherapy Management, Adherence & Specialty Pharmacy Coordination

16 Chapter 16: Clinical Trials, Biostatistics & Evidence Evaluation

16.1 Oncology Clinical Trial Designs, Endpoints & Statistical Power 16.2 Biostatistical Concepts: Hazard Ratios, Survival Analysis & Precision Metrics 16.3 Evidence Synthesis, Guideline Hierarchy & Critical Literature Appraisal

17 Chapter 17: Health Systems, Regulatory Compliance & Patient Education

17.1 Oncology Formulary Management, Biosimilars & Value Frameworks 17.2 Regulatory Mandates, REMS Programs & Investigational Drug Services 17.3 Patient & Caregiver Counseling, Survivorship Care & Palliative Ethics 17.4 Complementary, Alternative & Integrative Therapies in Oncology

17.4 Complementary, Alternative & Integrative Therapies in Oncology

Key Takeaways Explain This Topic AI

Up to 30-50% of patients with cancer use complementary approaches, usually without disclosing them; nonjudgmental supplement histories are a mandatory part of oncology medication reconciliation.

St. John's Wort potently induces CYP3A4 and P-glycoprotein, cutting exposure to oral oncolytics (imatinib, venetoclax, CDK4/6 inhibitors, irinotecan) and must be stopped with a washout before therapy; grapefruit inhibits CYP3A4 and raises TKI toxicity risk.

High-dose antioxidant supplements (vitamins C, E, beta-carotene) are discouraged during radiation and ROS-dependent chemotherapy because ROS scavenging can antagonize treatment; SELECT and CARET linked vitamin E and beta-carotene supplements to increased cancer risk.

ASCO-SIO integrative oncology guidelines support acupuncture/acupressure, mindfulness, massage, and music therapy as adjuncts for CINV, pain, anxiety, and fatigue; ginger, cannabinoids, and acetyl-L-carnitine must not replace guideline-directed antiemetic or neuropathy care.

Substituting alternative therapy for curative treatment approximately doubles cancer mortality; pharmacists counsel with authoritative resources (NCI PDQ, MSKCC About Herbs, NCCIH) and document every supplement decision.

Last updated: August 2026

1. Definitions, Prevalence & the Disclosure Gap

Blueprint task 2B7 (Complementary and Alternative Therapies) expects the oncology pharmacist to manage patients who use non-conventional therapies safely and without judgment. Complementary therapies are used alongside conventional treatment (e.g., acupuncture for nausea); alternative therapies are used instead of it; integrative oncology coordinates evidence-informed complementary modalities with conventional care. Surveys consistently show 30-50% of patients with cancer use some form of complementary approach , and the majority do not spontaneously disclose it to their oncology team — often because they fear disapproval. Every oncology medication reconciliation must therefore explicitly probe for vitamins, minerals, herbs, teas, and "natural" products.

2. Pharmacokinetic & Pharmacodynamic Interactions (High-Yield Table)

Product Mechanism Clinical Consequence Action

St. John's Wort Potent CYP3A4 / CYP2C19 / P-glycoprotein inducer Slashes exposure to imatinib, venetoclax, CDK4/6 inhibitors, irinotecan (SN-38 AUC down ~40%), docetaxel -> subtherapeutic treatment failure Discontinue (allow ~2-week washout) before oral oncolytics

Grapefruit / Seville orange / pomelo Intestinal CYP3A4 inhibition Raises exposure to many TKIs and oral agents -> toxicity Avoid during therapy with narrow-index CYP3A4 substrates

Green tea extract (EGCG) Catechin binds the boronic acid of bortezomib (in vitro) May antagonize proteasome inhibitor activity Discourage concentrated extracts during bortezomib; dietary tea in moderation is acceptable

High-dose biotin Interferes with streptavidin-biotin immunoassays Falsely LOW troponin/PSA/beta-hCG; falsely high free T4 -> misinterpreted monitoring and emergencies Hold >=48-72 hours before laboratory draws

Garlic, ginkgo, high-dose fish oil, curcumin Antiplatelet / anticoagulant potentiation Bleeding risk with surgery, thrombocytopenia, or anticoagulation Stop before procedures and during severe thrombocytopenia

Milk thistle (silymarin) Weak CYP2C9/3A4 modulation Minor interaction potential; generally tolerated Monitor; document

Echinacea / "immune boosters" Immunostimulation Theoretical antagonism of immunosuppression; caution around checkpoint-inhibitor irAE management Counsel on uncertainty; document

  • Kava, comfrey Direct hepatotoxicity Additive liver injury with hepatotoxic regimens Avoid
  • 3. Antioxidants, Phytoestrogens & Treatment-Antagonism Controversies

High-dose antioxidant supplements (vitamins C and E, beta-carotene, N-acetylcysteine) are discouraged during radiation therapy and ROS-dependent cytotoxic regimens (anthracyclines, platinums, alkylators) because reactive-oxygen-species scavenging may blunt treatment mechanisms; the SELECT trial linked vitamin E supplementation to increased prostate cancer risk, and CARET linked beta-carotene to increased lung cancer in smokers.

Soy/phytoestrogens in ER-positive breast cancer: moderate dietary intake appears safe and possibly beneficial; concentrated isoflavone supplements should be discouraged pending better data.

Laetrile ("vitamin B17") is ineffective and causes cyanide toxicity; high-dose IV vitamin C has no proven survival benefit and risks oxalate nephropathy and G6PD hemolysis; mistletoe extracts lack rigorous efficacy evidence and interact unpredictably.

"Alternative instead of curative" harm: observational data show patients who substitute alternative medicine for conventional curative cancer treatment have roughly double the risk of death ; the pharmacist's role is respectful redirection, never ridicule.